Exelixis

EXEL

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Insider trades and stock quote 2023-2025

All insider trades at Exelixis

Subscribe RSS
DateTypeInsiderPositionØ-PriceVolume
11/25/2025 BuyJohnson, David Edward Director $43.1 $1,187,235
11/21/2025 SellHaley, Patrick J. EVP, Commercial $42.6 $1,194,071
11/20/2025 SellHaley, Patrick J. EVP, Commercial $41.9 $1,852,857
11/12/2025 SellPapadopoulos, Stelios Director $43.6 $4,355,000
11/11/2025 SellBeckerle, Mary C. Director $42.0 $1,032,414
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)